spacer
home > ict > spring 2019 > the mosaic of patient engagement
PUBLICATIONS
International Clinical Trials

The Mosaic of Patient Engagement

Patient engagement is a ubiquitous concept in the orphan disease space, yet researchers are still vetting methods to implement more broadly based, efficient, and innovative interactions with patients and caregivers across the R&D spectrum. A wealth of potential engagement mechanisms have been suggested throughout the lifecycle of a potential therapeutic, highlighting both opportunities and challenges that can transform the R&D process.

What motivates someone to participate in a clinical trial? Enabling trial participation may require a fundamental shift in the way the pharmaceutical industry traditionally views the clinical trial process, changing the language commonly used to describe concepts such as patient recruitment and retention by adjusting the frame of reference to emphasise patient engagement. It is the patient’s journey, not the destination, that must take centre stage when a more strategic, rather than transactional, mandate is needed.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Barbara Zupancic is Senior Director of Patient Recruitment and Retention at Worldwide Clinical Trials. With nearly 20 years of experience in clinical research, she is responsible for the patient engagement aspects of clinical trials, which includes making trials more accessible to patients, less burdensome for sites, and smoother for sponsors.

Dr Michael Murphy is Chief Medical and Scientific Officer at Worldwide Clinical Trials. With 30 years of pharma experience, he is responsible for enabling strategic clinical research consultation and protocol development services for Phases 1-4 across therapeutic areas within Worldwide Clinical Trials.
spacer
Barbara Zupancic
spacer
spacer
spacer
Dr Michael Murphy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

Is Your Biobank Ready for the Challenge of Biomarker-based Research?

BioFortis

Targeted and personalized studies with well-defined patient segmentation biomarkers are becoming the norm in clinical trials. This increased interest in molecular biomarker studies necessitates a rigor and sophistication in sample management within the clinical trial context that is often not supported either by traditional clinical trial management software (CTMS), or biobanking systems.  Download our Next Generation Biobanking whitepaper and learn about how to overcome the key challenges in clinical trial sample management from working in a distributed network of partners and stakeholder to managing consents and generating scientific insights.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement